Maze Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURE PAGE
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| MAZE THERAPEUTICS, INC. | ||
| Date: March 25, 2026 | By: | /s/ Jason Coloma |
|---|---|---|
| Jason Coloma, Ph.D. | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Jason Coloma, Ph.D., Misbah Tahir and Courtney Phillips, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jason Coloma | Chief Executive Officer and Director | March 25, 2026 |
| Jason Coloma, Ph.D. | (Principal Executive Officer) | |
| /s/ Misbah Tahir | Chief Financial Officer | March 25, 2026 |
| Misbah Tahir | (Principal Financial Officer) | |
| /s/ Amy Bachrodt | SVP, Finance | March 25, 2026 |
| Amy Bachrodt | (Principal Accounting Officer) | |
| /s/ Hervé Hoppenot | Chairperson of our Board of Directors | March 25, 2026 |
| Hervé Hoppenot | ||
| /s/ Charles Homcy | Director | March 25, 2026 |
| Charles Homcy, M.D. | ||
| /s/ Nancy C. Andrews | Director | March 25, 2026 |
| Nancy C. Andrews, M.D., Ph.D. | ||
| /s/ Neil Exter | Director | March 25, 2026 |
| Neil Exter | ||
| /s/ Jonathan Lim | Director | March 25, 2026 |
| Jonathan Lim, M.D. | ||
| /s/ Richard Scheller | Director | March 25, 2026 |
| Richard Scheller, Ph.D. | ||
| /s/ Catherine Angell Sohn | Director | March 25, 2026 |
| Catherine Angell Sohn, Pharm. D. | ||
| /s/ Daniel Spiegelman | Director | March 25, 2026 |
| Daniel Spiegelman | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.